After entering 2026 hungry for deals, Gilead Sciences has wasted no time eating its fill. | After entering 2026 hungry for ...

The programme aims to nurture emerging agri-biotech ventures through incubation and institutional collaboration ...

NARO had assigned Dr Kiggundu to chair a committee constituted to reposition NARO’s Laboratory Centre of Excellence at the ...

An unusually mild winter followed by a wet spring made last year one of the worst in a decade for Pennsylvania soybean ...

Ho's new film Colony takes him back to the zombie genre after a decade of his award-winning classic Korean movie, Train to ...

He said U.S. losses alone top $500 billion a year and called gene drives “the only scalable” solution. As reported by 24/7 ...

As spring blooms across China and students enjoy their spring break, I traveled to Heze, a city in east China known as the "peony capital," home to more than 1,500 years of peony cultivation and 1,308 ...

Clinicians using one vendor's algorithm found lung squamous cell carcinoma misdiagnoses, influencing treatment decisions and ...

Artificial intelligence has long been seen as a way to supercharge drug development. | Artificial intelligence has long been seen as a way to supercharge drug development. But a whole new frontier of ...

Some investors are considering whether BioMarin Pharmaceutical's current share price reflects its underlying value, or if the market may be overlooking certain factors. The stock last closed at US$54.

Gilead Sciences has inked three deals this year so far totaling $14.77 billion, a marked escalation of the company’s usual ...

From cyber hubs to climate tech, a once-dismissed vision is transforming the South into a global laboratory for solutions ...